Satralizumab may be an effective option to reduce the frequency of relapse in patients with neuromyelitis optica spectrum disorder, an autoimmune disease leading to inflammatory demyelinating lesions of the spinal cord and optic nerves. Analyses of the phase 3 SAkuraSky and SAkuraStar studies seem promising, according to one presenter at the virtual Association for Research in Vision and Ophthalmology meeting.
“NMOSD is a debilitating disease of the central nervous system. Patients experience unpredictable relapses causing cumulative permanent neurological damage and disability. In some
Uncategorized